Cite
HARVARD Citation
Bellmunt, J. et al. (n.d.). 901PImpact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. Annals of oncology. p. . [Online].